All News

A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.

Epidiolex was approved to treat seizures associated with 2 rare and severe forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—in patients aged 2 years and older.

The CDC suggests that providers can better inform women about the recommended maternal vaccines.

Given the knowledge that a single pharmacy position can attract hundreds of applications, you must do everything possible to keep yourself in contention.

The American Society of Health-System Pharmacists (ASHP) has published guidelines with practical recommendations and best practices for preventing patient harm from medication errors.

A recent survey concluded that strategies to increase workplace immunization, such as requiring vaccination or promoting free onsite vaccines, lead to increased vaccination rates.

In light of new evidence supporting the efficacy of hepatitis C virus (HCV) treatments in individuals who use or inject drugs, researchers are urging the removal of restrictions that prevent recent drug users from accessing lifesaving HCV therapies.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Brain inflammation caused by critical illness and infection may lead to the observed reduction in brain volume.

The Drug Enforcement Administration is placing Epidiolex in Schedule V, the least restrictive of the Controlled Substances Act

Two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack are being voluntarily recalled by Endo Pharmaceuticals Inc., due to incorrent dosing information on the label.

Latest approval for carfilzomib offers a more convenient dosing option for patients with multiple myeloma.

A high-touch patient care model with enhanced data collection may help stop the ongoing opioid problem.

Metabolic syndrome involves multiple disease states including hypertension, hyperlipidemia, and possibly diabetes.

The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

According to FDA Commissioner Scott Gottlieb, MD, the agency’s approval of amikacin liposome inhalation suspension marks an important policy milestone.

Lymphatic vessels surrounding the brain may play a key role in the development and progression of multiple sclerosis.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Officials with the FDA have approved Admais’ 0.15mg Symjepi for the emergency treatment of allergic reactions, including anaphylaxis, in children.

A global survey found that 2 of 3 individuals with type 2 diabetes had experienced a cardiovascular disease (CVD) event or had CVD risk factors.

The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria in a limited population of patients with the disease who do not respond to conventional treatment.

Officials with the FDA have approved cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation.

Cemiplimab-rwlc (Libtayo) is the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma in the United States.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA®, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

Get involved this October and show your appreciation for the work pharmacists do.